Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer’s Prevnar 20 vaccine wins FDA approval 

By Brian Buntz | June 11, 2021

Pfizer-BioNTechPfizer’s (NSE:PFE) pneumococcal 13-valent conjugate vaccine Prevnar 13 is one of pharma’s bestsellers, earning nearly $6 billion last year.

Now, the company has scored FDA approval for its Prevnar 20 vaccine for adults 18 and older.

The vaccine is the first to offer protection against 20 serotypes of pneumococcal disease that cause the majority of pneumonia and invasive pneumococcal disease. In addition to the capsular polysaccharide conjugates already included in Prevnar 13, the new vaccine adds conjugates for seven different serotypes linked with invasive pneumococcal disease, antibiotic resistance and meningitis.

“With a single injection, Prevnar 20 provides adults with strong and meaningful protection against serotypes responsible for the majority of circulating pneumococcal disease around the world,” said Kathrin U. Jansen, senior vice president and head of vaccine research and development at Pfizer, in a statement.

Pfizer oversaw Phase 1 and 2 trials for the Prevnar 20 in addition to three Phase 3 studies for Prevnar 20.

Merck (NYSE:MRK) is currently working on an investigational 15-valent pneumococcal conjugate vaccine. The company now lags far behind Pfizer in terms of its pneumococcal vaccine sales.

Merck, however, recently announced that its V114 investigational 15-valent pneumococcal conjugate vaccine met its primary immunogenicity and safety endpoints in two studies.

Merck is also pursuing marketing authorization for the V114 vaccine.


Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tagged With: Merck, Pfizer, pneumococcal 13-valent conjugate, pneumococcal 20-valent conjugate, Prevnar 13, Prevnar 20, V114
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50